1
|
Sansonetti A, Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, Sardu C, Mileva N, Mauro C, Vassilev D, Marfella R, Calabro' P, Barbato E, Pizzi C. Infarct size, inflammatory burden and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) currently receive intense clinical interest in patients with and without diabetes mellitus (DM) with pleiotropic beneficial effects. Nowadays, the inflammation response in the setting of acute myocardial infarction (AMI) has been proposed as a potential pharmacological intervention target. In this setting, we tested the hypothesis that the SGLT2-I displays anti-inflammatory effect along with glucose-lowering properties. We investigated the relationship between stress hyperglycemia, inflammation burden and infarct size in a cohort of type 2 diabetic AMI patients treated with SGLT2-I versus other oral anti-diabetic (OAD) agents alone.
Methods
In this multicenter international registry, all diabetic patients with AMI treated with percutaneous coronary intervention (PCI) between 2018 and 2021 were enrolled. Based on the admission anti-diabetic therapy, patients were divided into those receiving SGLT2-I versus other OAD agents alone. Patients on insulin therapy alone or combined with OAD agents were excluded from the study. The following inflammatory markers were evaluated at different time points: total white blood cell, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and neutrophil-to-platelet ratio (NPR), C-reactive protein. Infarct size was assessed by peak troponin levels and echocardiographic parameters.
Results
The final study population consisted of 583 patients hospitalized for AMI (both STEMI and NSTEMI) classified as SGLT2-I users (n=98) versus other OAD agents alone (n=485). Admission hyperglycemia was more prevalent among the other OAD agents group. Reduced infarct size was detected in patients treated with SGLT2-I compared to those treated with other OAD agents alone. Both at admission, and after 24 hours, inflammatory indices were significantly higher in patients treated with other OAD agents alone, with a significant increase in neutrophils levels at 24 hours, compared to the SGLT2-I group. In multivariate analysis, SGLT2-I emerged as a significant predictor of reduced inflammatory response (OR 0.45, 95% CI 0.27–0.75, p=0.002), together with peak troponin values, independently of age, admission creatinine values and admission glycemia.
Conclusions
Type 2 Diabetic patients hospitalized for AMI and receiving SGLT2-I exhibited modest inflammatory response and myocardial damage/infarct size compared to other OAD agents alone, independently of glucose-metabolic control. Our findings pave the way for new pathophysiological and therapeutic insights regarding the cardioprotective effect of SGLT2-I in the setting of coronary artery disease.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Sansonetti
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - P Paolisso
- Cardiovascular Research Center Aalst , Aalst , Belgium
| | - L Bergamaschi
- University Hospital Policlinic S. Orsola-Malpighi, Cardiology, Department of Experimental Diagnostic and Specialty Medicine , Bologna , Italy
| | - G Santulli
- Montefiore Medical Center Albert Einstein College of Medicine , New York , United States of America
| | - E Gallinoro
- Cardiovascular Research Center Aalst , Aalst , Belgium
| | - A Cesaro
- Hospital Sant'anna E San Sebastiano , Caserta , Italy
| | - F Gragnano
- Hospital Sant'anna E San Sebastiano , Caserta , Italy
| | - C Sardu
- University of Campania Luigi Vanvitell , Naples , Italy
| | - N Mileva
- University Hospital Alexandrovska , Sofia , Bulgaria
| | - C Mauro
- AORN A. Cardarelli , Naples , Italy
| | | | - R Marfella
- University of Campania Luigi Vanvitell , Naples , Italy
| | - P Calabro'
- Hospital Sant'anna E San Sebastiano , Caserta , Italy
| | - E Barbato
- Cardiovascular Research Center Aalst , Aalst , Belgium
| | - C Pizzi
- University of Bologna , Bologna , Italy
| |
Collapse
|
2
|
Fimiani F, Gragnano F, Cesaro A, Vergara A, De Pasquale A, Blasi E, Calabro' P. Biochemical role of lipoprotein screening in patients with premature miocardial infarction and elite athletes. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Moscarella E, Calabro P, Gragnano F, Cesaro A, Pafundi P, Patti G, Cavallari I, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Sasso F, Pengo V, Gresele P, Marcucci R. Effect of body mass index on ischemic and bleeding events in patients presenting with acute coronary syndromes: insights from the START-ANTIPLATELET registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The protective effect of obesity on mortality in acute coronary syndromes (ACS) patients remains debated. We aimed at evaluating the impact of obesity on ischemic and bleeding events as possible explanations to the obesity paradox in ACS patients.
Methods
For the purpose of this sub-study, patients enrolled in the START-ANTIPLATELET registry were stratified according to Body Mass Index (BMI) into three groups: normal, BMI <25kg/m2; overweight, BMI: 25–29.9kg/m2; obese, BMI ≥30kg/m2. The primary endpoint was net adverse clinical endpoints (NACE), defined as a composite of all-cause death, myocardial infarction (MI), stroke, and major bleeding.
Results
Patients were classified as follows: 410 (33.9%) normal, 538 (44.5%) overweight, 261 (21.6%) obese. Compared to the normal weight group, obese and overweight patients had a higher prevalence of cardiovascular risk factors, but were younger, with a better left ventricular ejection fraction (LVEF) and lower PRECISE-DAPT score. At one-year follow-up NACE was more frequently observed in normal than in overweight and obese patients (15.1%,8.6%,and9.6%, respectively; p=0.004), driven by a significantly higher rate of all-cause death (6.3%,2.6%, and 3.8%, respectively; p=0.008), while no significant differences were noted in terms of MI, stroke, and major bleeding. When correcting for confounding variables, BMI loses its power in independently predicting outcomes, failing to confirm the obesity paradox in a real-world ACS population.
Conclusions
Our study conflicts the obesity paradox in real-world ACS population, and suggest that the reduced mortality rate may be explained by a lower bleeding risk in obese patients allowing a more aggressive medical treatment, and by a better LVEF translating into a higher survival rate.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- E Moscarella
- S. Anna-S. Sebastiano Hospital, University of Campania “Luigi Vanvitelli”, Caserta, Italy
| | - P Calabro
- S. Anna-S. Sebastiano Hospital, University of Campania “Luigi Vanvitelli”, Caserta, Italy
| | - F Gragnano
- S. Anna-S. Sebastiano Hospital, University of Campania “Luigi Vanvitelli”, Caserta, Italy
| | - A Cesaro
- S. Anna-S. Sebastiano Hospital, University of Campania “Luigi Vanvitelli”, Caserta, Italy
| | - P.C Pafundi
- university of Campania Luigi Vanvitelli, Naples, Italy
| | - G Patti
- University of L'Aquila, L'Aquila, Italy
| | | | | | | | | | | | - F.C Sasso
- university of Campania Luigi Vanvitelli, Naples, Italy
| | - V Pengo
- General University Hospital of Alicante, Alicante, Spain
| | - P Gresele
- University of Perugia, Perugia, Italy
| | | |
Collapse
|
4
|
Gragnano F, Moscarella E, Calabro' P, Cesaro A, Pafundi P, Patti G, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Pelliccia F, Sasso F, Pengo V, Gresele P, Marcucci R. Ticagrelor versus Clopidogrel in high bleeding risk patients presenting with Acute Coronary Syndromes: insights from the multicenter START-ANTIPLATELET registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Optimal dual antiplatelet therapy in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) remains debated. Although current guidelines recommend the use of potent P2Y12 inhibitors in these patients (according to the labeled indications), clopidogrel is frequently used in clinical practice based on a perceived advantage in terms of safety in the HBR population.
Purpose
We sought to investigate the use of clopidogrel versus ticagrelor in consecutive HBR ACS patients and their impact on ischemic and bleeding events at 1 year.
Methods
ACS patients enrolled in the START-ANTIPLATELET registry with at least 1 HBR criterion were included in the present analysis and stratified according to DAPT type (clopidogrel versus ticagrelor). The primary endpoint was net adverse clinical endpoint (NACE), defined as a composite of all-cause death, myocardial infarction, stroke, and major bleeding. The secondary endpoints were major adverse cardiac and cerebral events (MACE), defined as a composite of all-cause death, myocardial infarction and stroke, each individual component of NACE and MACE, and target vessel revascularization.
Results
Among a total of 1,209 patients with 1-year follow-up in the registry, 383 patients were considered at HBR, of whom 174 (45.4%) were on clopidogrel and 209 (54.6%) on ticagrelor. Clopidogrel was more likely to be administered in patients at increased ischemic and bleeding risk, while ticagrelor in those undergoing percutaneous coronary intervention. Mean DAPT duration was longer in the ticagrelor group than in the clopidogrel group (10.40±4.29 versus 9.35±5.4; p-value=0.03). At 1-year follow-up, the risk of NACE and MACE events was significantly higher in the clopidogrel than in the ticagrelor group (NACE: HR 1.82; 95% CI 1.07–3.09; p-value=0.02; MACE: HR 1.83; 95% CI 1.04–3.24; p-value=0.03) (Figure). After multivariate adjustment for clinical and procedural characteristics, no difference in NACEs nor MACEs was observed between patients on clopidogrel versus ticagrelor (NACE: adjusted HR 1.27; 95% CI 0.71–2.27; p-value=0.42; MACE: adjusted HR 1.19; 95% CI 0.63–2.24; p-value=0.59) (Figure). Age, number of HBR criteria, and mean DAPT duration were independent predictors of NACEs.
Conclusions
In a real-world ACS registry, approximately 50% of patients are at HBR and frequently treated with clopidogrel. In HBR ACS patients, no difference was observed in ischemic and bleeding events between clopidogrel and ticagrelor after adjustment for potential confounders.
Kaplan-Meier curves at 1-year follow-up.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- F Gragnano
- university of Campania Luigi Vanvitelli, Naples, Italy
| | - E Moscarella
- university of Campania Luigi Vanvitelli, Naples, Italy
| | - P Calabro'
- university of Campania Luigi Vanvitelli, Naples, Italy
| | - A Cesaro
- university of Campania Luigi Vanvitelli, Naples, Italy
| | - P.C Pafundi
- university of Campania Luigi Vanvitelli, Naples, Italy
| | - G Patti
- University of Eastern Piedmont, Novara, Italy
| | | | - P Cirillo
- Federico II University of Naples, Naples, Italy
| | | | | | | | - F.C Sasso
- university of Campania Luigi Vanvitelli, Naples, Italy
| | - V Pengo
- University of Padova, Padua, Italy
| | - P Gresele
- University of Perugia, Perugia, Italy
| | | |
Collapse
|
5
|
Fraiese A, Cesaro A, Belgiorno V, Sanromán MA, Pazos M, Naddeo V. Ultrasonic processes for the advanced remediation of contaminated sediments. Ultrason Sonochem 2020; 67:105171. [PMID: 32446202 DOI: 10.1016/j.ultsonch.2020.105171] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 05/06/2020] [Accepted: 05/08/2020] [Indexed: 06/11/2023]
Abstract
Sediments play a fundamental role in the aquatic environment, so that the presence of contaminants poses severe concern for the possible negative effects on both environmental and human health. Sediment remediation is thus necessary to reduce pollutant concentrations and several techniques have been studied so far. A novel approach for sediment remediation is the use of Advanced Oxidation Processes, which include ultrasound (US). This paper focuses on the study of the ultrasonic effects for the simultaneous reduction of both organic and inorganic contaminants from sediments. To this end, the US technology was investigated as a stand-alone treatment as well as in combination with an electro-kinetic (EK) process, known to be effective in the removal of heavy metals from soil and sediments. The US remediation resulted in higher organic compound degradation, with an average 88% removal, but promising desorption yields (47-84%) were achieved for heavy metals as well. The combined EK/US process was found to be particularly effective for lead. Experimental outcomes highlighted the potential of the ultrasonic technology for the remediation of contaminated sediments and addressed some considerations for the possible scale-up.
Collapse
Affiliation(s)
- A Fraiese
- Sanitary and Environmental Engineering Division (SEED), Department of Civil Engineering, University of Salerno, via Giovanni Paolo II, 132 - 84084 Fisciano, SA, Italy
| | - A Cesaro
- Department of Civil, Architectural and Environmental Engineering, University of Napoli Federico II, via Claudio 21, 80125 Napoli, Italy
| | - V Belgiorno
- Sanitary and Environmental Engineering Division (SEED), Department of Civil Engineering, University of Salerno, via Giovanni Paolo II, 132 - 84084 Fisciano, SA, Italy
| | - M A Sanromán
- CINTEX - Universidade de Vigo, Campus As Lagoas-Marcosende, University of Vigo, 36310 Vigo, Spain
| | - M Pazos
- CINTEX - Universidade de Vigo, Campus As Lagoas-Marcosende, University of Vigo, 36310 Vigo, Spain
| | - V Naddeo
- Sanitary and Environmental Engineering Division (SEED), Department of Civil Engineering, University of Salerno, via Giovanni Paolo II, 132 - 84084 Fisciano, SA, Italy.
| |
Collapse
|
6
|
Cesaro A, Gragnano F, Fimiani F, Moscarella E, Pariggiano I, Diana V, Carfora V, Conte M, Falato S, Cesarano M, Di Maio D, Calabrò P. Quality Of Life Improvement In High And Very High Cardiovascular Risk Patients Treated With Pcsk9 Inhibitors. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Biasioli S, Feriani M, Chiaramonte S, Cavallini L, Cesaro A, Fazion S, Petrosino L, Porena P, Zambello A. Different Buffers for Hemodiafiltration: A Controlled Study. Int J Artif Organs 2018. [DOI: 10.1177/039139888901200104] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Hemodiafiltration (HDF) is usually performed using a dialytic solution (D) containing acetate (A) or bicarbonate (B) and a replacement fluid (RF) containing lactate (L). To clarify the role of buffers in HDF, 11 patients underwent different study periods, each three months long: bicarbonate hemodialysis (BHD = Baseline period); HDF with (A) in D and (L) in RF (first period of HDF); HDF with (A) in D and (B) in RF (second HDF); HDF with (B) in D and (L) in RF (third HDF); HDF with (B) in D and (B) in RF (fourth HDF = BHDF). HDF achieved: 1) an increase in dialytic efficiency (kt/V, 1.28), reducing the time-session (197 min); 2) an improvement in acid-base status (pre-dialytic values in BHDF: pH 7.36; pCO2 39.8 mmHg; HCO−3 21.8 mM/L); 3) better “dry weight” gain (reached in 92.8% of HDF and in 81% of BHD sessions); 4) a significant decrease, in dialytic side-effects (mainly during the third and fourth periods). On the whole, BHDF (HDF done using only bicarbonate buffer) represents an easy and safe technique, leading to better cardiovascular stability than BHD and HDF without bicarbonate buffer.
Collapse
Affiliation(s)
- S. Biasioli
- Nephrology & Dialysis Unit, Legnago Hospital, Legnago - Italy
| | - M. Feriani
- Department of Nephrology & Dialysis, St. Bortolo Hospital, Vicenza - Italy
| | - S. Chiaramonte
- Department of Nephrology & Dialysis, St. Bortolo Hospital, Vicenza - Italy
| | - L. Cavallini
- Nephrology & Dialysis Unit, Legnago Hospital, Legnago - Italy
| | - A. Cesaro
- Nephrology & Dialysis Unit, Legnago Hospital, Legnago - Italy
| | - S. Fazion
- Nephrology & Dialysis Unit, Legnago Hospital, Legnago - Italy
| | - L. Petrosino
- Nephrology & Dialysis Unit, Legnago Hospital, Legnago - Italy
| | - P. Porena
- Nephrology & Dialysis Unit, Legnago Hospital, Legnago - Italy
| | - A. Zambello
- Nephrology & Dialysis Unit, Legnago Hospital, Legnago - Italy
| |
Collapse
|
8
|
De Vecchis R, Cesaro A. Therapeutic benefits of Phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis. Vascul Pharmacol 2018. [DOI: 10.1016/j.vph.2017.12.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
9
|
Di Iorio B, Cirillo M, Bellizzi V, Stellato D, De Santo NG, Aquino A, Anastasio P, Barchiesi S, Bonanno D, Buccino A, Cappabianca F, Cesaro A, Cestaro R, Chiuchiolo L, Chiuchiolo L, Ciaccia L, Cicchella T, Cillo N, Cioffi M, Cirillo E, Confessore N, Costanzo R, D'Apice L, De Felice E, Delgado G, De Luca M, De Luca P, De Luna V, De Maio A, De Pascale C, Della Volpe L, De Simone V, De Simone W, Di Benedetto A, Di Costanzo L, Di Donato R, Di Serafino A, Fabozzi GM, Fiorentino P, Fragetta G, Fumante M, Galise A, Giangrande C, Giobbe A, Gnasso A, Granato P, Guastaferro P, Iacono G, Iandolo R, Iengo G, Lamberti C, La Verde A, Liccardo D, Maddalena L, Mancini L, Manfreda L, Mari R, Marinelli G, Marinelli G, Martignetti V, Mascolini N, Maurodopoulos C, Migliorati M, Memoli M, Milone A, Milone D, Monaco G, Monteleone E, Natale G, Oggero AR, Pavese F, Petrelli P, Pizzola AR, Raucci B, Rubino R, Salvati G, Santoro D, Saviano C, Savignano M, Sforza C, Spitali L, Staulo P, Stellato D, Taddeo U, Terracciano V, Tomasino G, Tramontano P, Veniero P, Ventre M, Verrillo E, Violante B, Vitiello P, Viola G. Prevalence and Correlates of Anemia and Uncontrolled Anemia in Chronic Hemodialysis Patients – The Campania Dialysis Registry. Int J Artif Organs 2018. [DOI: 10.1177/039139880703000408] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background This study investigated prevalence and correlates of anemia and uncontrolled anemia in chronic hemodialysis patients. Methods A cross-sectional analysis was performed on registry data for 2,746 chronic (<6 months) hemodialysis patients aged 25–84. Data collection included years of dialysis, hours of dialysis/wk, disease causing hemodialysis, body mass index (BMI), erythropoietin (EPO) treatment, hemoglobin, markers of viral hepatitis, serum albumin, calcium, and phosphorus. Results Prevalence was 88.7% for anemia (hemoglobin <11 g/100 mL and EPO treatment at any Hb level), 39.4% for uncontrolled anemia (hemoglobin<11 g/100 mL). Gender, years of dialysis, hereditary cystic kidney disease (HCKD), and low BMI (<24 kg/m2) were independent correlates of anemia (P<0.001). Gender, HCKD, low BMI, serum albumin and calcium were independent correlates of uncontrolled anemia (P<0.05). An interaction was found between age (not correlated with anemia and uncontrolled anemia) and the association of gender with uncontrolled anemia (P<0.05). EPO doses were higher in patients with high prevalence of uncontrolled anemia than in patients with low prevalence (i.e., women vs men, other diseases vs HCKD, low vs not-low BMI, P<0.01). Gender, years of dialysis, HCKD, BMI, serum albumin, and calcium were independent correlates of the hemoglobin/EPO dose ratio in patients on EPO treatment (P<0.05). Conclusion Anemia and uncontrolled anemia are more frequent in hemodialysis patients with short-term dialysis, diseases other than HCKD, low BMI, and female gender. Gender effect was lower in elderly patients. Uncontrolled anemia was also associated with low serum albumin and calcium, suggesting that these parameters are indices of EPO resistance.
Collapse
Affiliation(s)
- B. Di Iorio
- Department of Nephrology, Second University of Naples, Naples - Italy
- Department of Nephrology, Solofra Hospital, Solofra - Italy
| | - M. Cirillo
- Department of Nephrology, Second University of Naples, Naples - Italy
| | - V. Bellizzi
- Department of Nephrology, Solofra Hospital, Solofra - Italy
| | - D. Stellato
- Department of Nephrology, Second University of Naples, Naples - Italy
| | - N. G. De Santo
- Department of Nephrology, Second University of Naples, Naples - Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Gragnano F, Concilio C, Cesaro A, Crisci M, Sperlongano S, Fimiani F, Natale F, Pezzullo E, Calabro' R, Russo M, Calabro' P. P1513Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1513] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Brain E, Corradengo D, Oriana N, Piccardo A, Matteucci F, Cortes J, Harbeck N, Würstlein R, Piris A, Alberini JL, Merlo DF, Degenhardt T, Turbiez I, Madar O, Monti M, Cesaro A, Rivitti E, Rollandi GA, Iacozzi M, Campazzi E, Campora S, Camporese D, Gennari A. Abstract OT3-03-03: Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The activation of international non-profit clinical trials funded by the European Commission (EC) is challenging given the cross-borders regulations and the need to follow specific timelines according to EC rules. We report here the logistic procedures and challenges faced by 4 academic centres from 4 different countries from the European Union (EU) for the activation of such program in metastatic breast cancer (MBC).
Materials and Methods
The primary objective of the ET-FES program is to validate the use of a new radiotracer 18F Fluoroestradiol (FES), targeting estrogen receptors, as a tool to better predict endocrine responsiveness in MBC, with PET/CT. The trial is sponsored by EO Galliera (Genoa, Italy) and brings together Italy, Spain, France and Germany. In 10/2012, ET-FES was approved for funding from EC under the Seventh Framework Programme after the first ERA-NET TRANSCAN Joint Transnational Call (JTC) for Proposals (2011) on validation of new biomarkers for personalized cancer medicine.
Results
The official start of the program was set up on 06/2013 by the Italian Ministry of Health. Time to institutional review board and to competent authority (CA) approvals were 1.5 and 11, 2 and 5, 3 and 16, and 13 and 14+ months in Italy, France, Spain and Germany respectively. Overall, no blocking comment was raised by the ethical committees; only minor clinical and methodological issues were raised in Germany and Spain. Issues from CA were raised in all countries except France (12, 21 and 23 queries in Italy, Spain and Germany respectively), on quality aspects of 18F-FES investigational medicinal product dossier. At the sponsor level, time to final agreement signature with Advanced Accelerator Applications, the 18F-FES manufacturing company, required 13 months. First patient could be enrolled in Italy 14 and 22 months after ethical committee approval and after the official start of the ET-FES project respectively.
Conclusions
As of May 2016, of 310 patients expected, only 28 have been enrolled from Italy. From a regulatory viewpoint and acknowledging that 18F-FES does not have yet any marketing approval in the EU, the ET-FES program approval process was timely completed at the ethical committee level in Italy, France and Spain. Time to CA approval varied across countries and was timely achieved only in France, due to requirements varying from CA to CA, stressing the serious lack of harmonized procedures although intended by the 2001/20/EC directive. Regarding sponsor's responsibilities (i.e. Italy), the administrative procedures needed to activate this type of EU projects remain critical, appealing for more tolerant time span in order to satisfy all the legal aspects on contracts by public bodies, according to national rules and laws. One needs to be very conscious of these timelines when applying to EU/EC calls, especially when the time allowed for the conduction of research is limited (3 years here), unless jeopardizing the entire multicentre and multinational effort.
Citation Format: Brain E, Corradengo D, Oriana N, Piccardo A, Matteucci F, Cortes J, Harbeck N, Würstlein R, Piris A, Alberini J-L, Merlo DF, Degenhardt T, Turbiez I, Madar O, Monti M, Cesaro A, Rivitti E, Rollandi GA, Iacozzi M, Campazzi E, Campora S, Camporese D, Gennari A. Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-03-03.
Collapse
Affiliation(s)
- E Brain
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - D Corradengo
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - N Oriana
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - A Piccardo
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - F Matteucci
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - J Cortes
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - N Harbeck
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - R Würstlein
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - A Piris
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - J-L Alberini
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - DF Merlo
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - T Degenhardt
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - I Turbiez
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - O Madar
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - M Monti
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - A Cesaro
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - E Rivitti
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - GA Rollandi
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - M Iacozzi
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - E Campazzi
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - S Campora
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - D Camporese
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| | - A Gennari
- Institut Curie / Hôpital René Huguenin, Saint-Cloud, France; E.O. Ospedali Galliera, Genova, Italy; IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - I.R.S.T., Meldola, Italy; Vall d´Hebrón Institute of Oncology, Barcelona, Spain; University of Munich, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Münich, Germany; IRCCS Azienda Osp. Univ. San Martino- IST, Genova, Italy; IBSA Institut Biochimique SA, Lugano, Switzerland; Covance, Milano, Italy; Advanced Accelerator Applications AAA, St Genis Pouilly, France
| |
Collapse
|
12
|
Brest P, Corcelle E, Cesaro A, Chargui A, Belaïd A, Klionsky D, Vouret-Craviari V, Hebuterne X, Hofman P, Mograbi B. Autophagy and Crohn's disease: at the crossroads of infection, inflammation, immunity, and cancer. Curr Mol Med 2010; 10:486-502. [PMID: 20540703 PMCID: PMC3655526 DOI: 10.2174/156652410791608252] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2009] [Accepted: 11/13/2009] [Indexed: 12/11/2022]
Abstract
Inflammatory bowel diseases (IBD) are common inflammatory disorders of the gastrointestinal tract that include ulcerative colitis (UC) and Crohn's disease (CD). The incidences of IBD are high in North America and Europe, affecting as many as one in 500 people. These diseases are associated with high morbidity and mortality. Colorectal cancer risk is also increased in IBD, correlating with inflammation severity and duration. IBD are now recognized as complex multigenetic disorders involving at least 32 different risk loci. In 2007, two different autophagy-related genes, ATG16L1 (autophagy-related gene 16-like 1) and IRGM (immunity-related GTPase M) were shown to be specifically involved in CD susceptibility by three independent genome-wide association studies. Soon afterwards, more than forty studies confirmed the involvement of ATG16L1 and IRGM variants in CD susceptibility and gave new information on the importance of macroautophagy (hereafter referred to as autophagy) in the control of infection, inflammation, immunity and cancer. In this review, we discuss how such findings have undoubtedly changed our understanding of CD pathogenesis. A unifying autophagy model then emerges that may help in understanding the development of CD from bacterial infection, to inflammation and finally cancer. The Pandora's box is now open, releasing a wave of hope for new therapeutic strategies in treating Crohn's disease.
Collapse
Affiliation(s)
- P. Brest
- Inserm ERI-21/EA 4319, Faculty of Medicine, University of Nice Sophia Antipolis, Nice, France
| | - E.A. Corcelle
- Apoptosis Department and Centre for Genotoxic Stress Research, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
| | - A. Cesaro
- Inserm ERI-21/EA 4319, Faculty of Medicine, University of Nice Sophia Antipolis, Nice, France
| | - A. Chargui
- Inserm ERI-21/EA 4319, Faculty of Medicine, University of Nice Sophia Antipolis, Nice, France
| | - A. Belaïd
- Inserm ERI-21/EA 4319, Faculty of Medicine, University of Nice Sophia Antipolis, Nice, France
| | - D.J. Klionsky
- University of Michigan, Life Sciences Institute, Ann Arbor, Michigan, USA
| | - V. Vouret-Craviari
- Inserm ERI-21/EA 4319, Faculty of Medicine, University of Nice Sophia Antipolis, Nice, France
| | - X. Hebuterne
- Inserm ERI-21/EA 4319, Faculty of Medicine, University of Nice Sophia Antipolis, Nice, France
- Centre Hospitalier Universitaire de Nice, Pôle Digestif, Hôpital L'Archet II, Nice, France
| | - P. Hofman
- Inserm ERI-21/EA 4319, Faculty of Medicine, University of Nice Sophia Antipolis, Nice, France
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France
| | - B. Mograbi
- Inserm ERI-21/EA 4319, Faculty of Medicine, University of Nice Sophia Antipolis, Nice, France
| |
Collapse
|
13
|
Brest P, Corcelle EA, Cesaro A, Chargui A, Belaid A, Klionsky D, Vouret-Craviari V, Hebuterne X, Hofman P, Mograbi B. Autophagy and Crohn's Disease: At the Crossroads of Infection,Inflammation, Immunity, and Cancer. Curr Mol Med 2010. [DOI: 10.2174/1566210205407035240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
14
|
Santamaria F, Andreucci MV, Parenti G, Polverino M, Viggiano D, Montella S, Cesaro A, Ciccarelli R, Capaldo B, Andria G. Upper airway obstructive disease in mucopolysaccharidoses: polysomnography, computed tomography and nasal endoscopy findings. J Inherit Metab Dis 2007; 30:743-9. [PMID: 17570075 DOI: 10.1007/s10545-007-0555-5] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2007] [Revised: 04/11/2007] [Accepted: 04/19/2007] [Indexed: 10/23/2022]
Abstract
In mucopolysaccharidoses, upper airway obstruction has multiple causative factors and progressive respiratory disease may severely affect morbidity and mortality. In a cross-sectional study over 2 years we evaluated upper airway obstructive disease through overnight polysomnography, upper airway computed tomography and nasal endoscopy in 5 children and 6 adults with mucopolysaccharidoses of various types. Measurements of apnoea and apnoea-hypopnoea index, arousal index, and sleep efficiency were obtained through polysomnography. Retropalatal and retroglossal spaces were calculated through computed tomography, and the degree of adenoid hypertrophy was assessed through endoscopy. Apnoea index and apnoea-hypopnoea index were significantly higher in children than in adults with mucopolysaccharidoses (p = 0.03 and p = 0.03, respectively). Compared to healthy controls, retropalatal and retroglossal spaces were significantly smaller in children (p = 0.03 and p = 0.004, respectively) or adults with mucopolysaccharidoses (p = 0.004 and p = 0.004, respectively). All subjects had adenoid hypertrophy causing first-degree (36%) or second-degree (64%) obstruction at endoscopy. Overnight polysomnography, upper airway computed tomography and nasal endoscopy are useful tools for diagnosing obstructive sleep apnoea syndrome in mucopolysaccharidoses, and identifying the site and severity of airway obstruction.
Collapse
Affiliation(s)
- F Santamaria
- Department of Pediatrics, Federico II University, Via Pansini 5, 80131, Naples, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Raia V, Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Auricchio S, Cimmino M, Cavaliere M, Nardone M, Cesaro A, Malcolm J, Quaratino S, Londei M. Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis. Thorax 2005; 60:773-80. [PMID: 15994249 PMCID: PMC1747526 DOI: 10.1136/thx.2005.042564] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Cystic fibrosis (CF) airways are characterised by chronic inflammation, increased interleukin (IL)-8 secretion, and neutrophil activation which are considered the principal factors of morbidity and mortality in CF patients. Optimising management of this chronic inflammatory response is therefore a key issue of basic and clinical CF research. Several reports have addressed ways to manage CF airways inflammation, and an attractive therapeutic strategy may be the inhibition of the p38-mitogen activated protein kinase (p38-MAP-k) pathway. METHODS A new ex vivo model was used to study the mucosal inflammatory response to environmental airways stimuli. Nasal biopsy tissues from CF patients and controls were cultured ex vivo for 20 minutes, 4 hours, and 24 hours in the presence of lipopolysaccharide (LPS) from Pseudomonas aeruginosa (PA) with and without the p38-MAP-k inhibitor SB203580. Quantitative mRNA assessment, immunohistochemistry, and Western blots were used to detect the expression and modulation of inflammatory markers. RESULTS PA-LPS challenge induced a time dependent mucosal inflammation indicated by rapid epithelial activation, IL-8 release, COX-2 upregulation, and neutrophil migration to the upper mucosal layers. Some of these LPS induced changes (IL-8 release and neutrophil migration) were specific to CF tissues. SB203580 significantly controlled all LPS induced mucosal changes in CF tissues. CONCLUSION These findings provide a rationale and proof of principle for the potential use of p38-MAP-k inhibitors to control inflammation in patients with CF.
Collapse
Affiliation(s)
- V Raia
- Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Pisani A, Uccello F, Cesaro A, Comi N, Mirenghi F, Serio V, Sabbatini M. [Effects of atorvastatin on ischemic acute renal failure in aging rats]. G Ital Nefrol 2002; 19:534-9. [PMID: 12439842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Abstract
BACKGROUND Aging (O) rats have a greater susceptibility to renal ischemia than young (Y) rats due to an endothelial dysfunction partially reversed by exogenous administration of L-Arginine. Since statins are able to increase nitric oxide (NO) production, aim of the study was to evaluate whether pre-treatment with atorvastatin (ATO, 10 mg/kg/day for 12 days), had positive effects on ischemic acute renal failure (ARF) of aging rats. METHODS Renal clearance studies (inulin) were performed 24 hours after ischemia in 6 Groups (n=6 in each Group) of both Y- and O-rats: control rats (CON), untreated rats with ARF (Groups IRA), and rats with ARF but pretreated with ATO (Groups ATO+IRA). RESULTS Renal ischemia determined a sharper decrease in GFR of Group O-IRA than Y-IRA (-80% and -63% vs respective CON, both p<0.001). In both Groups the fall in GFR was secondary to renal vasoconstriction and the consequent reduction in renal plasma flow. Pre-treatment with ATO did not modify GFR in Group Y-ATO+IRA, but was able to determine a marked rise in GFR of rats of O-ATO+IRA Group (+100% vs O-IRA), through a reduction in renal vascular resistances. Induction of ARF greatly enhanced nitrate excretion in Group Y-IRA, but slightly affected Group O-ARF. Administration of ATO did not modify nitrite excretion in Y rats, whereas it was able to increase nitrate excretion in O-ATO+ARF rats (+111% vs O-IRA). CONCLUSIONS Pre-treatment with ATO is able to improve the renal response to ischemia in aging rats, through a mechanism which likely is NO-dependent.
Collapse
Affiliation(s)
- A Pisani
- Cattedra di Nefrologia Medica, Universita' Federico II, Napoli, Italy
| | | | | | | | | | | | | |
Collapse
|
17
|
|
18
|
|
19
|
Bruckner S, Meille SV, Malpezzi L, Cesaro A, Navarini L, Tombolini R. The structure of poly(D-(-)-.beta.-hydroxybutyrate). A refinement based on the Rietveld method. Macromolecules 2002. [DOI: 10.1021/ma00182a021] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Pisani A, Uccello F, Cesaro A, Alfieri R, Comi N, Mirenghi F, Serio V, Sabbatini M. [Progression of chronic renal failure in remnant rats: role of arginase inhibition]. G Ital Nefrol 2002; 19:278-85. [PMID: 12195395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
BACKGROUND Oral administration of arginine to remnant (REM) rats (5/6 nx) slows the progression of chronic renal failure through a nitric-oxide(NO)-dependent mechanism. We have recently shown that inhibition of arginase, the main metabolic pathway of arginine, was able to induce similar results on renal dynamics (GIN: 2001, 18:285-290). Aim of the present study was to test whether these changes were mediated by increased availability of arginine-derived NO. Methods. Three Groups of REM rats were studied for 8 weeks after surgery: 1) untreated REM (Group REM); 2) REM rats treated with arginine (1%) in tap water (Group ARG); 3) REM rats administered a Mn++-free diet, to induce partial inhibition of arginase (Group MNF). Normal unmanipulated rats were used as controls (Group NOR). RESULTS Liver arginase activity was significantly depressed only in MNF-rats (-35% vs. REM, p < 0.01). Blood pressure was significantly lower in Group MNF vs. ARG and REM after 6 weeks (p < 0.05). Proteinuria was significantly decreased in Group ARG (-42%, p < 0.05 vs. REM) and even more in Group MNF (-57%, p < 0.01). ARG plasma levels, decreased in REM rats (-41% vs. Group CON), were normalized in Group ARG (p < 0.01 vs. Group REM); arginase inhibition was able to increase such levels in Group MNF (+38% vs. REM) and this resulted in a proportional rise in urinary nitrite excretion (+33% vs. REM), grossly depressed in REM rats. Renal arginase activity was lower in all the Groups of remnant rats vs. Group NOR, but intrarenal concentrations of ARG were significantly lower only in rats of Group MNF (p < 0.05 vs. all the other Groups). Histological examination showed that MNF-rats had a glomerular sclerosis index lower than in the other Groups (p < 0.05 vs. Group REM and ARG). CONCLUSIONS In conclusion, inhibition of arginase in remnant rats slows the progression of CRF and preserves renal histology through a direct and/or indirect NO-dependent mechanism.
Collapse
Affiliation(s)
- A Pisani
- Cattedra di Nefrologia Medica, Università degli Studi Federico II, Napoli
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Radetti G, Crepaz R, Milanesi O, Paganini C, Cesaro A, Rigon F, Pitscheider W. Cardiac performance in Turner's syndrome patients on growth hormone therapy. Horm Res 2002; 55:240-4. [PMID: 11740146 DOI: 10.1159/000050003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVES To investigate possible cardiac morphofunctional alterations observed in 26 Turner's syndrome (TS) patients on prolonged high-dose growth hormone (GH) therapy. STUDY DESIGN We examined 26 TS subjects treated with rhGH (1 U/kg/week) for a mean period of 4.9 years (range 1-7.8) and 37 age-, weight- and height-matched healthy girls. Left ventricular volume, mass, systolic function, cardiac index, systemic vascular resistance and diastolic function were evaluated by two-dimensional and Doppler echocardiography. RESULTS Heart rate and systolic blood pressure (BP) were higher in TS patients than in controls, while diastolic BP was lower. Left ventricular volumes, ejection fraction, mass index, M/V ratio and cardiac index did not differ significantly; systemic vascular resistance was slightly decreased. Left ventricular fractional shortening and mean velocity of circumferential shortening were slightly increased while end-systolic meridional stress was decreased in TS. Contractile state was normal in TS. Diastolic function assessment showed a shortening of isovolumetric relaxation and diastolic filling times with an increased atrial contribution and a normal pulmonary venous flow. CONCLUSION Cardiac morphology in TS patients on GH therapy is similar to controls. The observed changes in left ventricular systolic and diastolic function should be interpreted as an adaptation to the higher heart rate and reduced peripheral vascular resistance induced by GH therapy.
Collapse
Affiliation(s)
- G Radetti
- Department of Pediatrics, Regional Hospital of Bolzano, Italy.
| | | | | | | | | | | | | |
Collapse
|
22
|
|
23
|
Abstract
Abstract
Collapse
|
24
|
Petracca EG, Cesaro A, Biasioli S. [Clinical evaluation of 2 years of hemodiafiltration using bicarbonate]. Clin Ter 1990; 133:165-71. [PMID: 2142904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
At the end of a previous study concerning the use of different buffers for hemodiafiltration (BHDF) in both the re-infusate (40 mM/L) and dialysate (26 mM/L). Retrospective data analysis and showed BHDF to permit good acid/base balance, good clinical tolerability and satisfactory and persistent sense of well-being. From the point of view of kinetics, it is essential to evaluate carefully the acute and/or chronic effect of an alkaline blood pH during or after dial lysis, especially since the volume distribution of bicarbonate is not known.
Collapse
|
25
|
Biasioli S, Petrosino L, Cavallini L, Cesaro A, Fazion S, Zambello A, Foroni R, Mazzali A. Cardiovascular stability during the haemodialysis session: relationship between modelling and impedance parameters. Nephrol Dial Transplant 1990; 5 Suppl 1:137-40. [PMID: 2129445 DOI: 10.1093/ndt/5.suppl_1.137] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
The percentage of body water, if calculated from impedance, was found to be significantly different from the classic 58%. This supports the view that the evaluation of the dialytic efficiency should be, in the near future, carried out on the basis of a 'two-pool' model instead of the old 'one-pool'. The serial collection of data during a dialytic session supported the hypothesis that, 90 min after the start or, in general, after a body-water loss of about 5%-6%, some fundamental changes in measured indexes (phase angle, systolic pressure, body volumes, correlation matrix) usually appear. Large-scale research, based on an RS 232 interface connected to a computerised program, will probably help in clarifying whether some major intra-dialytic phenomena could in the near future be easily and automatically predicted.
Collapse
Affiliation(s)
- S Biasioli
- Nephrology and Dialysis Unit, Legnago Hospital, Italy
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Marchiori L, Rozio L, Bressan A, Biasoli S, Cesaro A, Peretti A, Tommasi I, Perbellini L. [Occupational arsine poisoning: description of a case]. Med Lav 1989; 80:330-4. [PMID: 2593970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A case of occupational arsine poisoning is described that occurred in a small family workshop during blackening operations on zinc/aluminium alloy manufactured parts with acid solutions. This report shows that occupational poisonings wrongly believed to have disappeared can still occur, especially in small and often unsafe working environments.
Collapse
|
27
|
Biasioli S, Petrosino Z, Cavalli L, Zambello A, Cesaro A, Fazion S. Bioelectrical impedance for the assessment of body composition of dialyzed patients. Clin Nephrol 1989; 31:274-5. [PMID: 2736817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
|
28
|
Biasioli S, Feriani M, Chiaramonte S, Cavallini L, Cesaro A, Fazion S, Petrosino L, Porena P, Zambello A. Different buffers for hemodiafiltration: a controlled study. Int J Artif Organs 1989; 12:25-30. [PMID: 2925257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Hemodiafiltration (HDF) is usually performed using a dialytic solution (D) containing acetate (A) or bicarbonate (B) and a replacement fluid (RF) containing lactate (L). To clarify the role of buffers in HDF, 11 patients underwent different study periods, each three months long: bicarbonate hemodialysis (BHD = Baseline period); HDF with (A) in D and (L) in RF (first period of HDF); HDF with (A) in D and (B) in RF (second HDF); HDF with (B) in D and (L) in RF (third HDF); HDF with (B) in D and (B) in RF (fourth HDF = BHDF). HDF achieved: 1) an increase in dialytic efficiency (kt/V, 1.28), reducing the time-session (197 min); 2) an improvement in acid-base status (pre-dialytic values in BHDF: pH 7.36; pCO2 39.8 mmHg; HCO3- 21.8 mM/L); 3) better "dry weight" gain (reached in 92.8% of HDF and in 81% of BHD sessions); 4) a significant decrease, in dialytic side-effects (mainly during the third and fourth periods). On the whole, BHDF (HDF done using only bicarbonate buffer) represents an easy and safe technique, leading to better cardiovascular stability than BHD and HDF without bicarbonate buffer.
Collapse
Affiliation(s)
- S Biasioli
- Nephrology & Dialysis Unit, Legnago Hospital, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Biasioli S, Foroni R, Cesaro A, Cavallini L, Petrosino L. [Computerization of "dialytic efficiency"]. MINERVA UROL NEFROL 1989; 41:81-2. [PMID: 2762978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
30
|
Biasioli S, Mazzali A, Foroni R, D'Andrea G, Feriani M, Chiaramonte S, Cesaro A, Micieli G. Chronobiological variations of prolactin (PRL) in chronic renal failure (CRF). Clin Nephrol 1988; 30:86-92. [PMID: 3180518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
During a 24-hour period, the serum levels of prolactin (PRL) were determined in 89 subjects, including 24 controls and 65 with chronic renal failure (CRF), divided into groups according to sex, age and serum creatinine. In mild CRF, both in males and females, PRL level proved to be higher than controls while its circadian rhythm of secretion disappeared. The MANOVA analysis (multivariate analysis of variance) showed that all 3 considered factors (sex, age, creatinine) have a systematic effect on PRL values, that of creatinine being the most prominent. With the progression of renal failure, the physiological PRL oscillations tended to diminish. In general, increasing creatinine levels progressively shifted the acrophase (that is the time-distance between a given hour and the maximum peak of the function) to the morning, with hemodialysis patients showing acrophases between 12 p.m. and 1 a.m. It is possible that in CRF the PRL feedback system could no longer function.
Collapse
Affiliation(s)
- S Biasioli
- Nephrology and Dialysis Unit, Legnago Hospital, Italy
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Paoletti S, Cesaro A, Delben F, Ciana A. Ionic Effects on the Conformation, Equilibrium, Properties, and Rheology of Pectate in Aqueous Solutions and Gels. ACTA ACUST UNITED AC 1986. [DOI: 10.1021/bk-1986-0310.ch007] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Affiliation(s)
- S. Paoletti
- Dipartimento di Biochimica, Biofisica e Chimica delle Macromolecole, Università di Trieste, Piazzale Europa 1, I-34127 Trieste, Italy
| | - A. Cesaro
- Dipartimento di Biochimica, Biofisica e Chimica delle Macromolecole, Università di Trieste, Piazzale Europa 1, I-34127 Trieste, Italy
| | - F. Delben
- Dipartimento di Biochimica, Biofisica e Chimica delle Macromolecole, Università di Trieste, Piazzale Europa 1, I-34127 Trieste, Italy
| | - A. Ciana
- Dipartimento di Biochimica, Biofisica e Chimica delle Macromolecole, Università di Trieste, Piazzale Europa 1, I-34127 Trieste, Italy
| |
Collapse
|
32
|
|